Watch TPST. Know when insiders buy.
One email the day a filing lands. Free.
TPST
Tempest Therapeutics, Inc.
0.81
−0.03 −3.36%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
45
WATCH · shorts 45
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $11.9MP/E —DIV YIELD —FCF YIELD -173.70%REV TTM —NET INCOME −$40.5MNET DEBT $3.4M52W 0.75 – 11.83SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$5.3M | −$5.2M | — | -0.34 | −$2.8M | $0 | −$2.8M | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$27.7M | −$27.7M | — | -2.53 | −$7.6M | $0 | −$7.6M | Aug 13 |
| Q4 2025 · Dec 31derived | — | — | — | −$4.1M | −$4M | — | -0.62 | −$3.6M | $0 | −$3.6M | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$3.6M | −$3.5M | — | -0.79 | −$6.8M | $0 | −$6.8M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$8M | −$7.9M | — | -2.07 | −$8.4M | $0 | −$8.4M | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$10.9M | −$10.9M | — | -3.16 | −$8M | $0 | −$8M | Aug 13 |
| Q4 2024 · Dec 31derived | — | — | — | −$13.9M | −$13.8M | — | -4.02 | −$10.1M | $3K | −$10.2M | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$10.6M | −$10.6M | — | -5.32 | −$10.2M | $15K | −$10.2M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$9.6M | −$9.6M | — | -5.52 | −$5.5M | $249K | −$5.8M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$8M | −$7.9M | — | -4.62 | −$7.2M | $168K | −$7.4M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$7.5M | −$7.5M | — | -0.34 | −$6.2M | $7K | −$6.2M | Mar 27 |
| Q3 2023 · Sep 30 | — | — | — | −$6.6M | −$6.8M | — | -0.48 | −$6.5M | $0 | −$6.5M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$26.6M | −$26.3M | — | -6.33 | −$26.8M | $0 | −$26.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$42M | −$41.8M | — | -19.50 | −$33M | $435K | −$33.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$29.2M | −$29.5M | — | -1.91 | −$27.4M | $170K | −$27.5M | — | — |
| FY2022 · to Dec 31 | — | — | −$34.6M | −$35.7M | — | -3.09 | −$31.1M | $562K | −$31.6M | — | — |
| FY2021 · to Dec 31 | — | — | −$27M | −$28.3M | — | -7.47 | −$26M | $135K | −$26.1M | — | — |
| FY2020 · to Dec 31 | — | — | −$19.3M | −$19.2M | — | -41.03 | −$19M | $50K | −$19.1M | — | — |
Every number comes from Tempest Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.